When Schering-Plough and Merck announced Nov. 19 they had been advised to change the scientific goal of a long-delayed clinical trial comparing the effectiveness of their blockbuster cholesterol Vytorin to a generic, the decision drew press scrutiny, criticism and a Congressional investigation.
The board voted last week to keep the name after an avalanche of criticism in November when it announced it was switching to the more generic Cancer Support Community Southwest Wisconsin, in part out of concern that young people today were unfamiliar with Radner, who died of ovarian cancer in 1989.